Get the Stockscreener App
216.97
2.31%
4.90
Pre-market:
214.76
-2.21
-1.02%
Natera Inc stock is traded at $216.97, with a volume of 1.02M.
It is up +2.31% in the last 24 hours and up +16.43% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$212.07
Open:
$213.64
24h Volume:
1.02M
Relative Volume:
0.73
Market Cap:
$31.07B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-132.20
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
+1.64%
1M Performance:
+16.43%
6M Performance:
-5.00%
1Y Performance:
+31.23%
1-Day Range:
$209.57
$219.44
1-Week Range:
$208.79
$224.70
52-Week Range:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
216.97 | 31.07B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
473.72 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
181.10 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
570.00 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
130.59 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
357.76 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera expands Austin operations with new sequencing facility - MSN
Natera to launch enhanced Panorama NIPT for low fetal fractions - MSN
Forget SpaceX Hype: Billionaire Stanley Druckenmiller is Loading Up on This Unknown Healthcare Stock - Insider Monkey
Morgan Stanley files Form 144 for 100,000 NTRA shares (NASDAQ: NTRA) - Stock Titan
Natera Inc Stock (US6323071042): Analyst calls from RBC and Goldman put diagnostics specialist in fo - AD HOC NEWS
Natera MRD Leadership Supported by 'Durable' High-Value Market, RBC Says - Moomoo
NTRA & Diakonos partner to use Signatera in refractory melanoma trial - MSN
RBC Capital Maintains Natera(NTRA.US) With Buy Rating, Cuts Target Price to $275 - Moomoo
RBC Capital initiates Natera stock coverage with outperform rating By Investing.com - Investing.com Australia
RBC Capital initiates Natera stock coverage with outperform rating - Investing.com
Natera (NTRA) Coverage Resumed with Positive Outlook and Price T - GuruFocus
NTRA & CytoDyn partner to advance ctDNA-guided development in mCRC - MSN
Natera director Marcus Boxer sells $2.39 million in stock - Investing.com UK
Natera director Marcus Boxer sells $2.39 million in stock By Investing.com - Investing.com South Africa
Natera (NTRA) director Boxer exercises options and sells 11,000 shares - Stock Titan
Natera : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Thomas J. Lynch Jr. joins Natera (NTRA) insider list with Form 3 filing - Stock Titan
Have Natera Insiders Been Selling Stock? - simplywall.st
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC - Yahoo Finance
Natera Pushes MRD And Panorama Into Treatment Guiding Roles - Yahoo Finance
Billionaire Stanley Druckenmiller Likes This Cancer Stock - Insider Monkey
How Investors May Respond To Natera (NTRA) Expanding Signatera MRD Reach Amid Insider Share Sale - simplywall.st
Natera, Inc. (NTRA) Stock Analysis: Insights into a High-Growth Diagnostics Leader with a 20% Upside Potential - DirectorsTalk Interviews
This Insider Has Just Sold Shares In Natera - Moomoo
Net income of Natera, Inc. – XETR:45E - TradingView
Assessing Natera (NTRA) Valuation After Strong Multi Year Returns And Recent Share Price Cooling - simplywall.st
5 Healthcare Stocks That the AI Crowd Is Overlooking - Barron's
Natera, Inc. Balance Sheet – XETR:45E - TradingView
Goldman Sachs Initiates Natera(NTRA.US) With Hold Rating, Announces Target Price $245 - Moomoo
Natera's EXPAND trial enrollment crosses 2,000 patient milestone - MSN
Insider Sell Alert: Steven Chapman Sells 41,124 Shares of Natera Inc (NTRA) - GuruFocus
Natera CEO Steven Chapman sells $9.09 million in company stock By Investing.com - Investing.com South Africa
Natera CEO Steven Chapman sells $9.09 million in company stock - Investing.com UK
Natera(NTRA.US) Officer Sells US$9.09 Million in Common Stock - Moomoo
Natera (NTRA) CEO Chapman sells 41,124 shares under 10b5-1 plan - Stock Titan
(NTRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
[144] Natera, Inc. SEC Filing - Stock Titan
Natera Expands Board, Appoints Thomas Lynch as Director - TipRanks
Natera (NTRA) appoints independent director Thomas Lynch and expands board - Stock Titan
Natera executive chairman sells $1.64m in shares - Investing.com
NTRA Initiates Coverage On Goldman Sachs -- Rating Set to Neutra - GuruFocus
Natera, Inc. Earnings and Revenue – XETR:45E - TradingView
Goldman Sachs initiates Natera stock with Neutral rating, $245 target - Investing.com UK
Goldman Sachs initiates Natera stock with Neutral rating, $245 target By Investing.com - Investing.com Australia
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.69%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):